We then analyzed the synergistic effect of the VEGF polymorphisms and clinical factors (i.e., HTN, DM, hemoglobin A1c, smoking, BMI, hyperlipidemia, MetS, folate, and homocysteine) on CAD risk (Table S7). This evidence concerns the gene VEGFA and hypertensive disorder.